Holen Sie sich die Stockscreener-App
2.01
1.01%
0.02
Schlusskurs vom Vortag:
$1.99
Offen:
$2.05
24-Stunden-Volumen:
503.83K
Relative Volume:
1.07
Marktkapitalisierung:
$190.12M
Einnahmen:
$72.76M
Nettoeinkommen (Verlust:
$35.34M
KGV:
5.4427
EPS:
0.3693
Netto-Cashflow:
$-62.91M
1W Leistung:
-1.47%
1M Leistung:
-29.72%
6M Leistung:
+33.11%
1J Leistung:
+21.82%
1-Tages-Spanne:
$1.96
$2.08
1-Wochen-Bereich:
$1.96
$2.12
52-Wochen-Spanne:
$1.295
$3.235
Compugen Ltd Stock (CGEN) Company Profile
Compare CGEN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGEN
Compugen Ltd
|
2.01 | 190.12M | 72.76M | 35.34M | -62.91M | 0.3693 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-07 | Eingeleitet | Lake Street | Buy |
| 2026-01-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-01-13 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-05 | Herabstufung | Jefferies | Buy → Hold |
| 2020-05-26 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2020-05-13 | Eingeleitet | Stifel | Buy |
| 2020-05-07 | Eingeleitet | SVB Leerink | Outperform |
| 2020-04-22 | Eingeleitet | ROTH Capital | Buy |
| 2020-03-24 | Eingeleitet | SunTrust | Buy |
| 2020-01-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-03-29 | Eingeleitet | Oppenheimer | Outperform |
| 2016-02-01 | Fortgesetzt | Oppenheimer | Outperform |
| 2015-10-15 | Eingeleitet | FBR Capital | Outperform |
| 2015-04-23 | Fortgesetzt | Jefferies | Buy |
| 2015-04-21 | Eingeleitet | Oppenheimer | Outperform |
| 2014-02-07 | Eingeleitet | MLV & Co | Buy |
| 2009-12-28 | Bestätigt | Cantor Fitzgerald | Buy |
| 2009-07-29 | Eingeleitet | Cantor Fitzgerald | Buy |
Alle ansehen
Compugen Ltd Aktie (CGEN) Neueste Nachrichten
Compugen presents ovarian cancer trial poster at ESMO meeting - Investing.com UK
Compugen presents ovarian cancer trial poster at ESMO meeting By Investing.com - Investing.com Canada
Compugen spotlights COM701 ovarian trial at ESMO congress - Stock Titan
Compugen Ltd (CGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Compugen Ltd (CGEN) Institutional Confidence - TradingKey
Compugen (CGEN) Stock Faces Mixed Analyst Target Changes After Cautious Valuation Revisions - Yahoo Finance UK
Compugen Ltd (CGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Compugen Ltd (CGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Compugen Ltd (CGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Compugen Ltd (CGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Compugen Ltd (CGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Compugen Ltd (CGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Compugen Ltd (CGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
CGEN Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Stage Continues; Stock DeclinesStrong Earnings Momentum - newsline.com
CGEN Q1 2026 Earnings: EPS Misses Estimates amid R&D FocusRevenue Beat Analysis - newsline.com
Compugen Ltd. (CGEN) Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Continues Development - newsline.com
Compugen Ltd (CGEN) to Present MAIA-Ovarian Trial Progress at Eu - GuruFocus
Compugen to present ovarian cancer trial poster at ESMO - Investing.com UK
Compugen to present ovarian cancer trial poster at ESMO By Investing.com - Investing.com South Africa
Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026 - Yahoo Finance
[EFFECT] COMPUGEN LTD SEC Filing - Stock Titan
AI cancer drug development talk with Compugen streams June 15 - Stock Titan
Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development - TradingView
CGEN STOCK : PRICE RECOVERY | COMPUGEN STOCK (kbWl8ONY7V) - Fathom Journal
CGEN Q1 2026 Earnings: EPS Misses Estimates as Stock Declines on No RevenueEarnings Call Highlights - newsline.com
H.C. Wainwright reiterates Compugen stock rating on ASCO data - Investing.com UK
H.C. Wainwright reiterates Compugen stock rating on ASCO data By Investing.com - Investing.com Canada
CGEN Q1 2026 Earnings: Wider-than-Expected Loss but Early-Stage Pipeline Progress Maintains MomentumFinancial Data - newsline.com
Why The Narrative Around Compugen (NasdaqCM:CGEN) Is Shifting After Analyst Resets And New Views - Yahoo Finance
Compugen Q1 2026 Earnings Call: Complete Transcript - Benzinga
Compugen Shares Slide 5.4% as Key Support Level ApproachesGrowth Stock Picks - newsline.com
Compugen (CGEN) Drops Nearly 4% as Stock Tests Key Support LevelsUndervalued Stocks - The Legal Advocate
Compugen surges after revenue tops forecasts despite quarterly loss miss (CGEN) - MSN
Earnings Preview: Compugen to Report Financial Results Pre-market on May 18 - Moomoo
Compugen Ltd (CGEN) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Compugen Ltd (CGEN) Stock Price, Trades & News - GuruFocus
Compugen (CGEN) Surges 7.28% as Shares Approach Key Resistance LevelBull Pennant - The Legal Advocate
Compugen Surges 7% as Biotech Stock Tests Key Resistance Levels (CGEN)Positive Gamma - thelegaladvocate.com
Compugen Ltd. Q1 2026 Earnings: Narrowing Losses but Misses EstimatesHot Momentum Watchlist - Newser
Compugen Q1 2026 earnings preview - MSN
Compugen Ltd. (CGEN) Q1 2026 Earnings: Earnings Miss Slightly but Shares Rally on Upcoming CatalystGuidance Update - Newser
CGEN Q1 2026 Earnings: EPS Misses Estimates but Stock Rises 7.28% on Pipeline ProgressOne-Time Loss Impact - newsline.com
Leerink Partners Maintains Compugen(CGEN.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
CGEN Maintains Outperform Rating -- Price Target Lowered to $5.0 - GuruFocus
Finanzdaten der Compugen Ltd-Aktie (CGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):